BioMarin completes Alesta Therapeutics acquisition
Analysis based on 6 articles · First reported Aug 19, 2026 · Last updated Sep 02, 2026
The acquisition is expected to strengthen BioMarin's rare disease pipeline and expand its addressable patient population, potentially supporting long-term growth. The deal's modest dilution to 2026 results and the upfront cash payment may slightly pressure near-term earnings, but the strategic fit and potential first-in-class oral therapy for HPP could positively influence investor sentiment.
BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics, a clinical-stage biotechnology company, for $275 million upfront plus up to $215 million in milestone payments. The deal, announced on August 18, 2026, and closed on September 1, 2026, centers on ALE1, an oral small molecule in Phase 1/2a trials for hypophosphatasia (HPP), a rare genetic bone disease. Alesta spun out all non-ALE1 assets and employees into a separate entity before closing, so BioMarin acquired only ALE1 and related intellectual property. ALE1 has potential to be the first oral therapy for HPP, which currently has only injectable treatments. The program will be integrated into BioMarin's Skeletal Conditions Business Unit. This is BioMarin's third major rare disease acquisition in the past year, following its $4.8 billion deal for Amicus Therapeutics. BioMarin plans to fund the deal with cash on hand and expects a modestly dilutive impact on 2026 financial results. The acquisition strengthens BioMarin's rare skeletal conditions portfolio, anchored by Voxzogo.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard